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comparators using Swedish-specific data, where available. Direct and indirect costs 
were reported in 2012 Euro [1 Euro (€ ) = 8.91 Swedish Krona] and an annual discount 
rate of 3% was applied on costs and effects. Results: With inclusion of indirect 
costs the cost-effectiveness analyses indicate that in dual therapy when compared 
to sitagliptin as add-on to metformin, canagliflozin appears to dominate sitagliptin 
with average cost savings of 718 € and an average QALY gain of 0.011 and as add-on 
to metformin canagliflozin appears to dominate sulfonylurea with average cost 
savings of 600 € and an average QALY gain of 0.063. As add-on to insulin canagliflo-
zin appears to dominate placebo with an incremental cost saving of 3339 € and an 
incremental QALY of 0.054. In mono therapy canagliflozin is cost-effective compared 
to sulfonylurea with an incremental cost-effectiveness ratio (ICER) of 1838 € per 
QALY. Probabilistic analysis of the four comparisons suggests a likelihood of above 
50% of canagliflozin being cost-effective. Sensitivity analyses show that canagliflo-
zin remains cost-effective when indirect costs were not included. ConClusions: 
Canagliflozin 100 mg and 300 mg (80/20 dose split) appears to be a cost-effective 
alternative to sitagliptin and glimepiride in dual therapy as add-on to metformin. 
Adding canagliflozin to insulin will be cost-effective compared with placebo. 
Canagliflozin is a cost-effective alternative to sulfonylurea in mono therapy.
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objeCtives: Point–of–care testing of blood glucose (BG–POCT) is essential for safe 
insulin infusion in critically ill patients. Costs associated with BG–POCT are consid-
ered substantial, especially when more frequent monitoring is needed as with strict 
glucose control aiming for lower BG–levels. The objective of this study is to estimate 
the incremental cost-effectiveness of a strict BG-POCT guideline versus a loose 
guideline, from a hospital perspective. Methods: This is a secondary analysis of 
a guideline implementation project aiming for normal BG–levels in three intensive 
care units in The Netherlands[1]. A Markov model including health states ‘target 
glucose’, ‘hyperglycemia’, ‘hypoglycemia’, and hospital death was developed to com-
pare expected costs, number of patients within target and number of life years 
saved before and after guideline implementation. Results: The analysis included 
1.321 and 2.175 patients 12 and 24 months before and after implementation of the 
guideline, respectively. The number of BG-POCT increased from 4.2 [2.6 – 6.7] to 8.7 
[4.1 – 11.2] per patient per day. Costs for BG–POCT increased with 72%. When taking 
total hospital costs and clinical effects into account, implementation of the strict 
glycemic control guideline reduces hospital costs with € 134 during total inpatient 
stay, as patients spend less time in hypo/hyperglycemic events and had shorter stays 
in ICU and hospital (–0.5 and –1.1 day, respectively). This translates into expected 
cost savings of € 13 per additional patient in target glucose and € 10 per additional 
life year saved. The model outcomes are most sensitive to changes in ICU length of 
stay. ConClusions: This health–economic analysis shows that additional costs 
of BG–POCT with implementation of a strict glucose control guideline are offset 
against savings generated by reduced hypo/hyperglycemic events and length of stay 
in ICU and hospital. [1] Schultz, M.J., et al. Minerva Anestesiol, 2012. 78(9): p. 982-95.
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objeCtives: To evaluate long-term cost-effectiveness of switching from human 
premix insulin to biphasic insulin aspart (BIAsp 30) in people with type 2 diabetes 
mellitus (T2DM) in China. Methods: The previously published and validated IMS 
Core Diabetes Model was used to project life expectancy, quality-adjusted life years 
(QALYs) and total direct medical costs over 30 years from a societal perspective. 
Patient characteristics and treatment effects were obtained from Chinese subgroup 
(n= 1191) in the A1chieve® observational study. After treatment with BIAsp 30 over 24 
weeks, patients’ HbA1c decreased by 1.6%, rate of major and minor hypoglycaemia 
decreased by 0.51 and 4.32 events per patient-year respectively. Treatment costs 
were based on insulin doses (35.8 IU daily for human premix insulin and 36.1 IU for 
BIAsp 30) and market retail prices in China. Management (concomitant medications, 
screening programmes, etc) and complication costs were obtained from Chinese 
published data in 2011 and adjusted to the price level of 2012 with the consumer 
price index. Costs and life years were discounted at 3% annually. One-way sensitiv-
ity analysis was performed. Results: Switching to BIAsp 30 from human premix 
insulin was projected to reduce incidence of most diabetes-related complications, 
increase life expectancy by 0.732 years (13.457 vs 12.725 ) and improve quality-
adjusted life years by 1.032 QALYs (9.487 vs 8.455) per patient. Although treatment 
and management costs increased by Chinese Yuan (CNY) 14,712 (52,329 vs. 37,617) 
and 1,857 (39,821vs. 37,964) respectively, complication costs reduced by CNY 96,198 
(104,752 vs. 200,950); switching to BIAsp 30 from human premix insulin was asso-
ciated with reduced total direct medical cost of CNY 79,628 (196,902 vs. 276,530). 
Sensitivity analyses demonstrated robustness of the results. ConClusions: 
Switching to BIAsp 30 from human premix insulin was associated with improve-
ments in life expectancy and QALYs, and was a cost-saving treatment strategy for 
people with T2DM in China.
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glycemic control, leading to a reduced incidence of diabetes-related complications, 
including renal disease, cardiovascular disease, ophthalmic and diabetic foot com-
plications. Liraglutide was associated with increased direct costs (EUR 56,628 versus 
EUR 52,450), driven by the acquisition cost of liraglutide. However, this was partially 
offset by the reduced cost of treating diabetes-related complications. Based on these 
estimates, liraglutide was associated with an incremental cost-effectiveness ratio 
of EUR 10,436 per QALY gained versus sitagliptin. ConClusions: Liraglutide 1.8mg 
was projected to improve clinical outcomes over sitagliptin as a result of reduced 
incidence of diabetes-related complications. Liraglutide is likely to be cost-effective 
from a health care payer perspective in Spain.
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objeCtives: Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as exena-
tide once weekly (EQW) and liraglutide (LIRA), are FDA-approved as treatment 
for type 2 diabetes mellitus (T2DM). Head-to-head studies and meta-analyses of 
these agents have reached different conclusions about their relative effective-
ness. Methods: We developed a decision-analytic model to evaluate the likely 
incremental cost-effectiveness of EQW versus LIRA 1.8 mg in T2DM patients, with 
effectiveness measured as reduction in glycated hemoglobin (HbA1c). The model 
structure tracks change in HbA1c and direct medical expenditure (drug, needle, 
adverse events [AEs]) over a 26-week time horizon, and allows patients to discon-
tinue treatment due to AEs (nausea, diarrhea, vomiting, constipation, dyspepsia) 
after 1 or 3 months of therapy. Patients discontinuing treatment are assumed to 
return to their baseline HbA1c. We compared the outcomes (cost per 1% and 0.2% 
reduction in HbA1c) of models populated with clinical data from a head-to-head 
26-week randomized, controlled trial (DURATION-6) and a meta-analysis conducted 
by Scott and colleagues (2012). Drug costs and other utilization costs were based 
on wholesale acquisition costs and published sources. Results: For the base 
case, the projected total 6-month cost of EQW versus LIRA was $2,444 and $3,054, 
respectively. Using data from DURATION-6 and meta-analysis, compared with EQW, 
LIRA had a projected incremental cost per 1% reduction in HbA1c (ICER) of $3,262 
and $18,578 over a 6-month time horizon, respectively. Compared with EQW, the 
projected 6-month cost per 0.2% reduction in HbA1c for LIRA was $652 and $3,716 
based on data from DURATION-6 and meta-analysis, respectively. ConClusions: 
The projected cost per 1% reduction in HbA1c was lower with EQW than liraglutide 
1.8 mg at 6 months. The difference in projected cost per HbA1c reduction varies 
significantly depending on the trial-based data sources used. Real-world data are 
needed to resolve the current uncertainties.
PDB71
cost-EffEctivEnEss analysis of hcg anD human gonaDotroPins in 
mEn with hyPogonaDotroPic hyPogonaDism in thE contExt of an 
assistED rEProDuction Program
Chamberland C.
Institut national d’excellence en santé et en services sociaux, Québec, QC, Canada
objeCtives: To evaluate the efficiency, in terms of incremental cost-effectiveness 
ratios (ICER), of human chorionic gonadotropin (hCG) and human gonadotropins, 
drugs used for male infertility due to hormonal disorder hypogonadotropic hypo-
gonadism (HH), whose female partner has or doesn’t have infertility problems, in 
the context of an assisted reproduction program. Methods: Two different decision 
trees were developed to assess ICER of hCG and human gonadotropins. Firstly, hCG 
was compared to no treatment; secondly, human gonadotropins in combination 
with hCG were compared to hCG used alone. Effectiveness was measured as preg-
nancy and spermatogenesis respectively. Data were obtained from clinical studies, 
as well as efficacy of medical procedures. The proportion of couples, who needed 
fertility procedures, was determined according to experts’ opinion. A ministry of 
health perspective was taken. Costs of medications were based on acquisition costs 
in 2012 Canadian dollars. Costs of medical procedures, as intrauterine insemination 
(IUI), in vitro fertilisation (IVF) and intra cytoplasmic sperm injection (ICSI) were 
based on 2012 fees of Québec’s physicians. The time horizons adopted were based 
on the durations of drug treatment in clinical studies. Results: The use of hCG 
in comparison with no treatment is cost-effective with an ICER of 20,915$CAN per 
man with HH for whom the partner got pregnant. Determinist sensitivity analyses 
showed that the ratio is more sensitive to the probability to use IVF or ICSI. In the 
second comparison, treatment with human gonadotropins is cost-effective with 
an ICER of 25,076$CAN per man that obtained spermatogenesis. Drug dosage is the 
element for which the ICER is more sensitive in the univariate determinist sensitiv-
ity analyses. ConClusions: Human gonadotropins and hCG are cost-effective for 
the treatment of men with HH. They can be reimbursed in the drug program for this 
indication with some restrictions about the duration of treatment.
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objeCtives: To evaluate the cost-effectiveness of canagliflozin in dual therapy as 
add-on to metformin compared to sitagliptin and glimepiride, as add on to insulin 
(plus metformin) and in mono therapy compared to sulfonylurea in the Swedish 
setting from a societal perspective. Methods: The IMS CORE Diabetes Model was 
used to evaluate the cost-effectiveness of canagliflozin (using a weighted average 
of 80/20 for the 100 mg and 300 mg dosage respectively) versus the aforementioned 
